AKKARAJU SRINIVAS 4

What Happened Akkaraju Srinivas, a director of Kalaris Therapeutics, was granted an option covering 9,000 shares on June 3, 2026. The award is reported as a derivative grant with a reported price of $0.00 and a total reported value of $0. This is a grant/award (not a purchase or sale) and the shares are subject to vesting.

Key Details

• Transaction date: June 3, 2026; Form 4 filed June 4, 2026 (appears timely).
• Transaction type/code: Award/Grant (A); derivative option for 9,000 shares; reported price $0.00.
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnote: The option vests in full on the earlier of (i) June 3, 2027 or (ii) the date of Kalaris’s 2027 Annual Meeting of Stockholders, subject to continued service.
• No immediate sale or exercise reported (this is a future vesting award).

Context This filing documents an equity compensation award to a director — an option that will only convert to vested shares if service continues and vesting conditions are met. It does not reflect an exercise or sale; any future exercise or sale would generate additional filings. Awards to directors are common as compensation and do not by themselves indicate insider buying or selling sentiment.